Novartis’ Cosentyx® (secukinumab) superior to Stelara (ustekinumab) in delivering lasting skin clearance (PASI 90) for psoriasis patients at 52 weeks
Mar 05, 2016
New data at AAD 2016 shows Cosentyx® is significantly more efficacious than Stelara in sustaining skin clearance (PASI 90 to PASI 100) at 52 weeks1
Cosentyx delivered and sustained skin clearance (PASI 90 to PASI 100) in nearly 8 out of 10 moderate-to-severe psoriasis patients1
Cosentyx launched as first-line systemic indication for psoriasis in UK in 2015 and recently approved for psoriatic arthritis and ankylosing spondylitis in Europe
Frimley March 5, 2016 – Novartis announced today new late-breaking data from the head-to-head CLEAR study, demonstrating that Cosentyx (secukinumab) remains superior to Stelara (ustekinumab) in achieving sustained skin clearance (PASI 90 response) at 52 weeks for adults living with moderate-to-severe psoriasis. These findings were presented for the first time at the American Academy of Dermatology (AAD) Annual Meeting in Washington, DC1.
Cosentyx is the first fully human interleukin-17A inhibitor approved for adults to treat moderate-to-severe plaque psoriasis, and was also recently approved for the treatment of psoriatic arthritis and ankylosing spondylitis in Europe.
“Cosentyx continues to demonstrate superior and sustainable efficacy against currently available biologics and is a proven first-line treatment option for adult patients with moderate-to-severe psoriasis,” said Vasant Narasimhan, Global Head, Drug Development and Chief Medical Officer, Novartis. “Cosentyx has the potential to give more people with psoriasis than ever before the benefit of long-lasting skin clearance.”
The ultimate aim of psoriasis treatment is clear skin, and the Psoriasis Area Severity Index (PASI) 90 response is considered an important measure of treatment success 2,3. Meeting all primary and secondary endpoints at Weeks 4, 16 and 52, Cosentyx demonstrated it remains consistently superior to Stelara in achieving and sustaining PASI 90 response (76.2% vs. 60.6%; P<0.0001), and significantly better in achieving PASI 100 (clear skin) response (45.9% vs. 35.8%; P=0.0103) at 52 weeks 1,4. Cosentyx also showed significantly greater and sustained Dermatology Life Quality Index (DLQI) 0/1 responses versus Stelara (71.6% vs. 59.2%; P=0.0008) at 52 weeks1.
The study also demonstrated Cosentyx had a superior rapid onset of action compared to Stelara, with half of Cosentyx patients achieving PASI 75 as early as Week 4 (50.0% vs. 20.6%, P<0.0001)4. Cosentyx had a similar safety profile to that of Stelara in the study, which was consistent with that reported in the pivotal Cosentyx Phase III studies1. Psoriasis is a chronic inflammatory condition which is estimated to affect between 2% and 3% of the UK population – up to 1.8 million people5. Psoriasis causes itching, scaling and pain, and can have a significant impact on physical and psychological wellbeing6. Despite this, up to half of patients receive no treatment, and of those who do, many (52%) remain dissatisfied with their disease management8.
About psoriasis Psoriasis is a common, non-contagious, autoimmune disease that affects up to 3% of the UK population5. Plaque psoriasis is the most common form of the disease and appears as raised, red patches covered with a silvery white buildup of dead skin cells. Psoriasis is not simply a cosmetic problem, but a persistent, chronic (long-lasting), and sometimes distressing disease, which can affect even the smallest aspects of people’s lives on a daily basis 5,6.
About the CLEAR study CLEAR (Comparison to assess Long-term Efficacy, sAfety and toleRability of secukinumab vs. ustekinumab) is a multi-centre, double-blind, parallel-group study of Cosentyx (n=334) versus Stelara (n=335) to compare efficacy, safety and tolerability in adults with moderate-to-severe plaque psoriasis. Patients were randomized to receive either Cosentyx (300 mg) by subcutaneous injection at Baseline, Weeks 1, 2 and 3, then every 4 weeks from Week 4, or Stelara (dosing per package label). Cosentyx achieved the primary objective of superior PASI 90 response at Week 16. These data were published as an e-publication in the Journal of the American Academy of Dermatology, June 17, 20154. The 52-week PASI 90 response is a secondary objective in this study. PASI 100 and DLQI responses at 52 weeks are exploratory endpoints.
About Cosentyx and interleukin-17A (IL-17A) Cosentyx is a fully human monoclonal antibody that selectively neutralizes circulating IL-17A. Research suggests that IL-17A may play an important role in driving the body’s immune response in psoriasis, psoriatic arthritis and ankylosing spondylitis 8,9.
Cosentyx is approved in over 50 countries for the treatment of moderate-to-severe plaque psoriasis which includes the European Union countries, Japan, Switzerland, Australia, the US and Canada. In Europe, Cosentyx is the only biologic approved for the first-line systemic treatment of moderate-to-severe plaque psoriasis in adult patients.
In addition, Cosentyx is the first IL-17A inhibitor with positive Phase III results for the treatment of active psoriatic arthritis and active ankylosing spondylitis 10-13 and is now approved in Europe and the US for these conditions.
Disclaimer The foregoing release contains forward-looking statements that can be identified by words such as “continues,” “potential,” “aim,” “can,” “will,” “suggests,” “may,” or similar terms, or by express or implied discussions regarding potential new indications or labelling for Cosentyx, or regarding potential future revenues from Cosentyx. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Cosentyx will be submitted or approved for any additional indications or labelling in any market, or at any particular time. Nor can there be any guarantee that Cosentyx will be commercially successful in the future. In particular, management’s expectations regarding Cosentyx could be affected by, among other things, the uncertainties inherent in research and development, including unexpected clinical trial results and additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company’s ability to obtain or maintain proprietary intellectual property protection; general economic and industry conditions; global trends toward health care cost containment, including ongoing pricing pressures; unexpected safety issues; unexpected manufacturing or quality issues, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 119,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit http://www.novartis.com. Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.
1. Blauvelt A et al. Secukinumab demonstrates superior sustained efficacy vs. ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: 52-week results from the CLEAR study. 74th Annual Meeting of the American Academy of Dermatology, 4-8 Mar 2016, Washington DC (oral presentation by D Thaçi on 5 Mar 2016). 2. Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis 2004. European Medicines Agency website. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003329.pdf . Accessed March 2016. 3. Ryan C et al. Research gaps in psoriasis: opportunities for future studies. J Am Acad Dermatol. 2014; 70:146-167. 4. Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. June 17, 2015 [E-pub ahead of print]. 5. Psoriasis Association. About Psoriasis. https://www.psoriasis- association.org.uk/pages/view/about-psoriasis [Last accessed March 2016] 6. International Federation of Psoriasis Associations (IFPA) World Psoriasis Day website. “About Psoriasis.” Available at: http://www.worldpsoriasisday.com/web/page.aspx?refid=114. Accessed March 2016. 7. Armstrong AW et al. Under treatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol. 2013; 149(10):1180-1185. 8. Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014; 74:423–441. 9. Kirkham BW et al. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2014; 141:133-142. 10. Baeten D et al. Secukinumab, interleukin-17A inhibition in ankylosing spondylitis. N Engl J Med. 2015; 373:2534-48. 11. Mease, PJ et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2015; 386(9999):1137-1146. 12. Mease PJ et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015; 373(14):1329-39. 13. Cosentyx Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Product_Information/human/003729/WC500183129.pdf . Accessed March 2016.